Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma

Jae Yong Cho, Joo Hang Kim, Yi Hyeong Lee, Kyung Young Chung, Sung Kyu Kim, Soo Jung Gong, Nae Choon You, Hyun Cheol Chung, Jae Kyung Roh, Byung Soo Kim

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

BACKGROUND. Mutations at codons 12, 13, and 61 of the three ras genes. H-ras K-ras and N-ras, convert these genes into active oncogenes. It appears that ras gene mutations can be found in a variety of tumor types. The purpose of this study was to evaluate the clinical significance of K-ras gene mutation in nonsmall cell lung carcinoma (NSCLC). METHODS. The authors analyzed 58 NSCLC patients for mutations at codons 12, 13, and 61 of the K- ras gene and correlated the findings with the tumor stage and patient survival. Polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and the direct nucleotide sequencing method were used to detect mutations after amplification of ras specific sequences by PCR. RESULTS. Fourteen mutations (24%) of ras genes were found, all at codon 12 of the K- ras gene. GGT to GAT transition was the predominant mutational pattern. There was a significant association between K-ras mutation and the tumor stage (i.e., the higher the stage, the higher the mutation rate) (P = 0.014). Using univariate analysis the presence of K-ras mutation in paraffin embedded tissue from patients who received treatment with curative intent was associated with a shorter survival (P = 0.039). The median survival duration for patients with or without K-ras mutation was 9 and 30 months, respectively. The Cox proportional hazards model also predicted a higher risk for patients with K-ras mutations (P = 0.047). CONCLUSIONS. K-ras mutations present in a subset of NSCLC are associated with tumor progression and shortened patient survival.

Original languageEnglish
Pages (from-to)462-467
Number of pages6
JournalCancer
Volume79
Issue number3
DOIs
Publication statusPublished - 1997 Feb 1

Fingerprint

ras Genes
Carcinoma
Lung
Mutation
Codon
Survival
Neoplasms
Polymerase Chain Reaction
Mutation Rate
Oncogenes
Proportional Hazards Models
Paraffin
Nucleotides

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Cho, Jae Yong ; Kim, Joo Hang ; Lee, Yi Hyeong ; Chung, Kyung Young ; Kim, Sung Kyu ; Gong, Soo Jung ; You, Nae Choon ; Chung, Hyun Cheol ; Roh, Jae Kyung ; Kim, Byung Soo. / Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma. In: Cancer. 1997 ; Vol. 79, No. 3. pp. 462-467.
@article{45f713ab25804f9fa27103da8db5e570,
title = "Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma",
abstract = "BACKGROUND. Mutations at codons 12, 13, and 61 of the three ras genes. H-ras K-ras and N-ras, convert these genes into active oncogenes. It appears that ras gene mutations can be found in a variety of tumor types. The purpose of this study was to evaluate the clinical significance of K-ras gene mutation in nonsmall cell lung carcinoma (NSCLC). METHODS. The authors analyzed 58 NSCLC patients for mutations at codons 12, 13, and 61 of the K- ras gene and correlated the findings with the tumor stage and patient survival. Polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and the direct nucleotide sequencing method were used to detect mutations after amplification of ras specific sequences by PCR. RESULTS. Fourteen mutations (24{\%}) of ras genes were found, all at codon 12 of the K- ras gene. GGT to GAT transition was the predominant mutational pattern. There was a significant association between K-ras mutation and the tumor stage (i.e., the higher the stage, the higher the mutation rate) (P = 0.014). Using univariate analysis the presence of K-ras mutation in paraffin embedded tissue from patients who received treatment with curative intent was associated with a shorter survival (P = 0.039). The median survival duration for patients with or without K-ras mutation was 9 and 30 months, respectively. The Cox proportional hazards model also predicted a higher risk for patients with K-ras mutations (P = 0.047). CONCLUSIONS. K-ras mutations present in a subset of NSCLC are associated with tumor progression and shortened patient survival.",
author = "Cho, {Jae Yong} and Kim, {Joo Hang} and Lee, {Yi Hyeong} and Chung, {Kyung Young} and Kim, {Sung Kyu} and Gong, {Soo Jung} and You, {Nae Choon} and Chung, {Hyun Cheol} and Roh, {Jae Kyung} and Kim, {Byung Soo}",
year = "1997",
month = "2",
day = "1",
doi = "10.1002/(SICI)1097-0142(19970201)79:3<462::AID-CNCR6>3.0.CO;2-K",
language = "English",
volume = "79",
pages = "462--467",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma. / Cho, Jae Yong; Kim, Joo Hang; Lee, Yi Hyeong; Chung, Kyung Young; Kim, Sung Kyu; Gong, Soo Jung; You, Nae Choon; Chung, Hyun Cheol; Roh, Jae Kyung; Kim, Byung Soo.

In: Cancer, Vol. 79, No. 3, 01.02.1997, p. 462-467.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma

AU - Cho, Jae Yong

AU - Kim, Joo Hang

AU - Lee, Yi Hyeong

AU - Chung, Kyung Young

AU - Kim, Sung Kyu

AU - Gong, Soo Jung

AU - You, Nae Choon

AU - Chung, Hyun Cheol

AU - Roh, Jae Kyung

AU - Kim, Byung Soo

PY - 1997/2/1

Y1 - 1997/2/1

N2 - BACKGROUND. Mutations at codons 12, 13, and 61 of the three ras genes. H-ras K-ras and N-ras, convert these genes into active oncogenes. It appears that ras gene mutations can be found in a variety of tumor types. The purpose of this study was to evaluate the clinical significance of K-ras gene mutation in nonsmall cell lung carcinoma (NSCLC). METHODS. The authors analyzed 58 NSCLC patients for mutations at codons 12, 13, and 61 of the K- ras gene and correlated the findings with the tumor stage and patient survival. Polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and the direct nucleotide sequencing method were used to detect mutations after amplification of ras specific sequences by PCR. RESULTS. Fourteen mutations (24%) of ras genes were found, all at codon 12 of the K- ras gene. GGT to GAT transition was the predominant mutational pattern. There was a significant association between K-ras mutation and the tumor stage (i.e., the higher the stage, the higher the mutation rate) (P = 0.014). Using univariate analysis the presence of K-ras mutation in paraffin embedded tissue from patients who received treatment with curative intent was associated with a shorter survival (P = 0.039). The median survival duration for patients with or without K-ras mutation was 9 and 30 months, respectively. The Cox proportional hazards model also predicted a higher risk for patients with K-ras mutations (P = 0.047). CONCLUSIONS. K-ras mutations present in a subset of NSCLC are associated with tumor progression and shortened patient survival.

AB - BACKGROUND. Mutations at codons 12, 13, and 61 of the three ras genes. H-ras K-ras and N-ras, convert these genes into active oncogenes. It appears that ras gene mutations can be found in a variety of tumor types. The purpose of this study was to evaluate the clinical significance of K-ras gene mutation in nonsmall cell lung carcinoma (NSCLC). METHODS. The authors analyzed 58 NSCLC patients for mutations at codons 12, 13, and 61 of the K- ras gene and correlated the findings with the tumor stage and patient survival. Polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and the direct nucleotide sequencing method were used to detect mutations after amplification of ras specific sequences by PCR. RESULTS. Fourteen mutations (24%) of ras genes were found, all at codon 12 of the K- ras gene. GGT to GAT transition was the predominant mutational pattern. There was a significant association between K-ras mutation and the tumor stage (i.e., the higher the stage, the higher the mutation rate) (P = 0.014). Using univariate analysis the presence of K-ras mutation in paraffin embedded tissue from patients who received treatment with curative intent was associated with a shorter survival (P = 0.039). The median survival duration for patients with or without K-ras mutation was 9 and 30 months, respectively. The Cox proportional hazards model also predicted a higher risk for patients with K-ras mutations (P = 0.047). CONCLUSIONS. K-ras mutations present in a subset of NSCLC are associated with tumor progression and shortened patient survival.

UR - http://www.scopus.com/inward/record.url?scp=0010973499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0010973499&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19970201)79:3<462::AID-CNCR6>3.0.CO;2-K

DO - 10.1002/(SICI)1097-0142(19970201)79:3<462::AID-CNCR6>3.0.CO;2-K

M3 - Article

C2 - 9028355

AN - SCOPUS:0010973499

VL - 79

SP - 462

EP - 467

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -